S&P 500   4,512.33 (+0.58%)
DOW   35,405.69 (+0.42%)
QQQ   374.10 (+0.39%)
AAPL   148.63 (+1.42%)
MSFT   308.02 (+0.24%)
FB   339.62 (+1.28%)
GOOGL   2,853.59 (-0.07%)
TSLA   868.69 (-0.16%)
AMZN   3,435.25 (-0.33%)
NVDA   221.35 (-0.39%)
BABA   172.73 (+3.54%)
NIO   39.72 (+0.28%)
CGC   13.41 (+1.59%)
GE   104.37 (+0.24%)
AMD   115.91 (-0.45%)
MU   66.70 (-0.83%)
T   25.38 (+0.20%)
F   15.49 (-0.45%)
ACB   6.97 (+0.72%)
DIS   170.46 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.05 (-0.43%)
AMC   42.58 (-1.05%)
S&P 500   4,512.33 (+0.58%)
DOW   35,405.69 (+0.42%)
QQQ   374.10 (+0.39%)
AAPL   148.63 (+1.42%)
MSFT   308.02 (+0.24%)
FB   339.62 (+1.28%)
GOOGL   2,853.59 (-0.07%)
TSLA   868.69 (-0.16%)
AMZN   3,435.25 (-0.33%)
NVDA   221.35 (-0.39%)
BABA   172.73 (+3.54%)
NIO   39.72 (+0.28%)
CGC   13.41 (+1.59%)
GE   104.37 (+0.24%)
AMD   115.91 (-0.45%)
MU   66.70 (-0.83%)
T   25.38 (+0.20%)
F   15.49 (-0.45%)
ACB   6.97 (+0.72%)
DIS   170.46 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.05 (-0.43%)
AMC   42.58 (-1.05%)
S&P 500   4,512.33 (+0.58%)
DOW   35,405.69 (+0.42%)
QQQ   374.10 (+0.39%)
AAPL   148.63 (+1.42%)
MSFT   308.02 (+0.24%)
FB   339.62 (+1.28%)
GOOGL   2,853.59 (-0.07%)
TSLA   868.69 (-0.16%)
AMZN   3,435.25 (-0.33%)
NVDA   221.35 (-0.39%)
BABA   172.73 (+3.54%)
NIO   39.72 (+0.28%)
CGC   13.41 (+1.59%)
GE   104.37 (+0.24%)
AMD   115.91 (-0.45%)
MU   66.70 (-0.83%)
T   25.38 (+0.20%)
F   15.49 (-0.45%)
ACB   6.97 (+0.72%)
DIS   170.46 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.05 (-0.43%)
AMC   42.58 (-1.05%)
S&P 500   4,512.33 (+0.58%)
DOW   35,405.69 (+0.42%)
QQQ   374.10 (+0.39%)
AAPL   148.63 (+1.42%)
MSFT   308.02 (+0.24%)
FB   339.62 (+1.28%)
GOOGL   2,853.59 (-0.07%)
TSLA   868.69 (-0.16%)
AMZN   3,435.25 (-0.33%)
NVDA   221.35 (-0.39%)
BABA   172.73 (+3.54%)
NIO   39.72 (+0.28%)
CGC   13.41 (+1.59%)
GE   104.37 (+0.24%)
AMD   115.91 (-0.45%)
MU   66.70 (-0.83%)
T   25.38 (+0.20%)
F   15.49 (-0.45%)
ACB   6.97 (+0.72%)
DIS   170.46 (-0.40%)
PFE   41.90 (+1.40%)
BA   216.05 (-0.43%)
AMC   42.58 (-1.05%)
NASDAQ:CYCC

Cyclacel Pharmaceuticals Stock Forecast, Price & News

$5.36
-0.21 (-3.77 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.26
$5.54
50-Day Range
$4.54
$6.02
52-Week Range
$3.12
$11.42
Volume64,185 shs
Average Volume306,945 shs
Market Capitalization$49.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
30 days | 90 days | 365 days | Advanced Chart
Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Cyclacel Pharmaceuticals logo

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Sales & Book Value

Annual Sales
$150,000.00
Book Value
$5.32 per share

Profitability

Net Income
$-8.44 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$49.49 million
Next Earnings Date
11/10/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

879th out of 1,361 stocks

Pharmaceutical Preparations Industry

427th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

Is Cyclacel Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Cyclacel Pharmaceuticals?

Wall Street analysts have given Cyclacel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cyclacel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Cyclacel Pharmaceuticals
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings data on Tuesday, August, 10th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.09.
View Cyclacel Pharmaceuticals' earnings history
.

How has Cyclacel Pharmaceuticals' stock price been impacted by COVID-19?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYCC shares have increased by 892.8% and is now trading at $5.36.
View which stocks have been most impacted by COVID-19
.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on the morning of Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for CYCC?

1 equities research analysts have issued twelve-month price targets for Cyclacel Pharmaceuticals' stock. Their forecasts range from $17.00 to $17.00. On average, they anticipate Cyclacel Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 217.2% from the stock's current price.
View analysts' price targets for Cyclacel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:
  • Spiro Rombotis, President, Chief Executive Officer & Director
  • Paul McBarron, Secretary, Chief Operating & Financial Officer
  • Mark Kirschbaum, Chief Medical Officer & Senior Vice President
  • Amartya Basu, Senior Director-Business Development

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.16%).
View institutional ownership trends for Cyclacel Pharmaceuticals
.

Which institutional investors are buying Cyclacel Pharmaceuticals stock?

CYCC stock was bought by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Cyclacel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $5.36.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals has a market capitalization of $49.49 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-8.44 million in net income (profit) each year or ($3.87) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

Cyclacel Pharmaceuticals employs 2,018 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

Where are Cyclacel Pharmaceuticals' headquarters?

Cyclacel Pharmaceuticals is headquartered at 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at (908) 517-7330 or via email at [email protected].


This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.